EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis BioSpace
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis PR Newswire
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis Digital Journal
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis ACCESS Newswire
FinancialContent - Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis FinancialContent
Primary dysmenorrhea is painful menstruation in the absence of pelvic pathology, whereas secondary dysmenorrhea is menstrual pain attributable to an underlying pelvic disease (e.g., endometriosis). Nonsteroidal anti-inflammatory drugs (NSAIDs) are …
The pathogenesis and progression of endometriosis may involve a complex combination of multiple factors, including chronic inflammation and oxidative stress. Hormonal therapy, the current standard for pharmacotherapy in endometriosis, causes …
FimmCyte Partners with Gedeon Richter to Advance Non-Hormonal Endometriosis Treatment Femtech Insider
Endometriosis is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, non-hormonal therapies is urgently needed. We …
Endometriosis is a chronic, estrogen-dependent inflammatory condition that affects approximately 10% of reproductive-age women and is frequently associated with infertility and pelvic pain. Unlike many estrogen-dependent disorders, epidemiologic studies have …